Table of Contents
Molecular Biology International
Volume 2011 (2011), Article ID 306928, 13 pages
http://dx.doi.org/10.4061/2011/306928
Review Article

Experimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones

Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, 21040-900 Rio de Janeiro, RJ, Brazil

Received 4 January 2011; Revised 25 February 2011; Accepted 21 March 2011

Academic Editor: Hemanta K. Majumder

Copyright © 2011 Solange L. de Castro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. O. C. Rocha, M. M. Teixeira, and A. L. Ribeiro, “An update on the management of Chagas cardiomyopathy,” Expert Review of Anti-Infective Therapy, vol. 5, no. 4, pp. 727–743, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Rassi Jr., A. Rassi, and J. A. Marin-Neto, “Chagas disease,” The Lancet, vol. 375, no. 9723, pp. 1388–1402, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. B. L. Herwaldt, “Laboratory-acquired parasitic infections from accidental exposures,” Clinical Microbiology Reviews, vol. 14, no. 4, pp. 659–688, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. J. D. Altclas, L. Barcan, C. Nagel, R. Lattes, and A. Riarte, “Organ transplantation and Chagas disease,” Journal of the American Medical Association, vol. 299, no. 10, pp. 34–35, 2008. View at Google Scholar · View at Scopus
  5. M. Steindel, L. Kramer Pacheco, D. Scholl et al., “Characterization of Trypanosoma cruzi isolated from humans, vectors, and animal reservoirs following an outbreak of acute human Chagas disease in Santa Catarina State, Brazil,” Diagnostic Microbiology and Infectious Disease, vol. 60, no. 1, pp. 25–32, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. G. A. Schmunis, “Epidemiology of Chagas disease in non-endemic countries: the role of international migration,” Memórias do Instituto Oswaldo Cruz, vol. 102, supplement 1, pp. 75–85, 2007. View at Google Scholar · View at Scopus
  7. J. C. P. Dias, A. Prata, and D. Correia, “Problems and perspectives for Chagas disease control: in search of a realistic analysis,” Revista da Sociedade Brasileira de Medicina Tropical, vol. 41, no. 2, pp. 193–196, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Abad-Franch, W. S. Santos, and C. J. Schofield, “Research needs for Chagas disease prevention,” Acta Tropica, vol. 115, no. 1-2, pp. 44–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. J. R. Coura and J. Borges-Pereira, “Chagas disease: 100 years after its discovery. A systemic review,” Acta Tropica, vol. 115, no. 1-2, pp. 5–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Clayton, “Chagas disease: pushing through the pipeline,” Nature, vol. 465, no. 7301, pp. S12–S15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. M. B. Bilate and E. Cunha-Neto, “Chagas disease cardiomyopathy: current concepts of an old disease,” Revista do Instituto de Medicina Tropical de São Paulo, vol. 50, no. 2, pp. 67–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Junqueira, B. Caetano, D. C. Bartholomeu et al., “The endless race between Trypanosoma cruzi and host immunity: iessons for and beyond Chagas disease,” Expert Reviews in Molecular Medicine, vol. 12, p. e29, 2010. View at Google Scholar
  13. M. D. L. Higuchi, L. A. Benvenuti, M. M. Reis, and M. Metzger, “Pathophysiology of the heart in Chagas' disease: current status and new developments,” Cardiovascular Research, vol. 60, no. 1, pp. 96–107, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. A. P. Marino, A. A. Silva, P. V. Santos et al., “CC-chemokine receptors: a potential therapeutic target for Trypanosoma cruzi-elicited myocarditis,” Memórias do Instituto Oswaldo Cruz, vol. 100, no. 1, pp. 93–96, 2005. View at Google Scholar · View at Scopus
  15. C. Chagas, “Nova tripanosomíase humana—estudos sobre a morfologia e o ciclo evolutivo de Schizotrypanum cruzi gen. nov. sp. nov., agente etiológico de nova entidade mórbida do homem,” Memórias do Instituto Oswaldo Cruz, vol. 1, pp. 159–218, 1909. View at Google Scholar
  16. J. C. P. Dias, “Globalization, inequity and Chagas disease,” Cadernos de Saúde Pública, vol. 23, supplement 1, pp. S13–S22, 2007. View at Google Scholar · View at Scopus
  17. J. R. Coura, “Chagas disease: what is known and what is needed—a background article,” Memórias do Instituto Oswaldo Cruz, vol. 102, supplement 1, pp. 113–122, 2007. View at Google Scholar · View at Scopus
  18. J. R. Coura and S. L. De Castro, “A critical review on chagas disease chemotherapy,” Memórias do Instituto Oswaldo Cruz, vol. 97, no. 1, pp. 3–24, 2002. View at Google Scholar · View at Scopus
  19. M. N. C. Soeiro, A. P. Dantas, A. Daliry et al., “Experimental chemotherapy for Chagas disease: 15 years of research contributions from in vivo and in vitro studies,” Memórias do Instituto Oswaldo Cruz, vol. 104, supplement 1, pp. 301–310, 2009. View at Google Scholar
  20. L. S. Filardi and Z. Brener, “Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 81, no. 5, pp. 755–759, 1987. View at Google Scholar · View at Scopus
  21. W. Apt, “Current and developing therapeutic agents in the treatment of Chagas disease,” Drug Design, Development and Therapy, vol. 4, pp. 243–253, 2010. View at Google Scholar
  22. R. Viotti, C. Vigliano, B. Lococo et al., “Long-term cardiac outcomes of treating chronic chagas disease with benznidazole versus no treatment: a nonrandomized trial,” Annals of Internal Medicine, vol. 144, no. 10, pp. 724–734, 2006. View at Google Scholar · View at Scopus
  23. R. Viotti and C. Vigliano, “Etiological treatment of chronic Chagas disease: neglected ‘evidence’ by evidence-based medicine,” Expert Review of Anti-Infective Therapy, vol. 5, no. 4, pp. 717–726, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. J. A. Marin-Neto, A. Rassi Jr., C. A. Morillo et al., “Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole evaluation for interrupting Trypanosomiasis (BENEFIT),” American Heart Journal, vol. 156, no. 1, pp. 37–43, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Brener, J. R. Cançado, L. M. Galvão et al., “An experimental and clinical assay with ketoconazole in the treatment of Chagas disease,” Memórias do Instituto Oswaldo Cruz, vol. 88, no. 1, pp. 149–153, 1993. View at Google Scholar · View at Scopus
  26. A. Solari, H. Saavedra, C. Sepulveda et al., “Successful treatment of Trypanosoma cruzi encephalitis in a patient with hemophilia and AIDS,” Clinical Infectious Diseases, vol. 16, no. 2, pp. 255–259, 1993. View at Google Scholar · View at Scopus
  27. W. Apt, A. Arribada, I. Zulantay et al., “Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment,” Annals of Tropical Medicine and Parasitology, vol. 99, no. 8, pp. 733–741, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. F. S. Buckner and N. Navabi, “Advances in Chagas disease drug development: 2009-2010,” Current Opinion in Infectious Diseases, vol. 23, no. 6, pp. 609–616, 2010. View at Publisher · View at Google Scholar
  29. M. J. Pinazo, G. Espinosa, M. Gállego, P. L. López-Chejade, J. A. Urbina, and J. Gascón, “Case report: successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus,” American Journal of Tropical Medicine and Hygiene, vol. 82, no. 4, pp. 583–587, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. N. C. Soeiro and S. L. De Castro, “Novel promising synthetic trypanocidal agents against Trypanosoma cruzi: in vitro and in vivo studies,” Open Medicinal Chemistry Journal. In press.
  31. A. J. Romanha, S. L. de Castro, M. N. C. Soeiro et al., “In vitro and in vivo experimental models for drug screening and development for Chagas disease,” Memórias do Instituto Oswaldo Cruz, vol. 105, no. 2, pp. 233–238, 2010. View at Google Scholar · View at Scopus
  32. S. Nwaka and A. Hudson, “Innovative lead discovery strategies for tropical diseases,” Nature Reviews Drug Discovery, vol. 5, no. 11, pp. 941–955, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. M. N. C. Soeiro and S. L. De Castro, “Trypanosoma cruzi targets for new chemotherapeutic approaches,” Expert Opinion on Therapeutic Targets, vol. 13, no. 1, pp. 105–121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. J. A. Urbina, “Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches,” Acta Tropica, vol. 115, no. 1-2, pp. 55–68, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Rivera, V. Bocanegra-García, C. Ordaz-Pichardo, B. Nogueda-Torres, and A. Monge, “New therapeutic targets for drug design against Trypanosoma cruzi, advances and perspectives,” Current Medicinal Chemistry, vol. 16, no. 25, pp. 3286–3293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. D. R. M. Moreira, A. C. L. Leite, R. R. dos Santos, and M. B. P. Soares, “Approaches for the development of new anti-Trypanosoma cruzi agents,” Current Drug Targets, vol. 10, no. 3, pp. 212–231, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Sánchez-Sancho, N. E. Campillo, and J. A. Páez, “Chagas disease: progress and new perspectives,” Current Medicinal Chemistry, vol. 17, no. 5, pp. 423–452, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. J. R. Coura, “Present situation and new strategies for chagas disease chemotherapy—a proposal,” Memórias do Instituto Oswaldo Cruz, vol. 104, no. 4, pp. 549–554, 2009. View at Google Scholar · View at Scopus
  39. G. Benaim, J. M. Sanders, Y. Garcia-Marchán et al., “Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole,” Journal of Medicinal Chemistry, vol. 49, no. 3, pp. 892–899, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. R. A. Sánchez-Delgado and A. Anzelloti, “Metal complexes as chemotherapeutic agents against tropical diseases: trypanosomiasis, malaria and leishmaniasis,” Mini-Reviews in Medicinal Chemistry, vol. 4, no. 1, pp. 23–30, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. J. J. N. Silva, W. R. Pavanelli, F. R. Gutierrez et al., “Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy,” Journal of Medicinal Chemistry, vol. 51, no. 14, pp. 4104–4114, 2008. View at Publisher · View at Google Scholar
  42. P. M. Guedes, F. S. Oliveira, F. R. Gutierrez et al., “Nitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas' disease,” British Journal of Pharmacology, vol. 160, no. 2, pp. 270–282, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Ferella, D. Nilsson, H. Darban et al., “Proteomics in Trypanosoma cruzi- Localization of novel proteins to various organelles,” Proteomics, vol. 8, no. 13, pp. 2735–2749, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Parodi-Talice, R. Durán, N. Arrambide et al., “Proteome analysis of the causative agent of Chagas disease: Trypanosoma cruzi,” International Journal for Parasitology, vol. 34, no. 8, pp. 881–886, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. H. M. Andrade, S. M. F. Murta, A. Chapeaurouge, J. Perales, P. Nirdé, and A. J. Romanha, “Proteomic analysis of Trypanosoma cruzi resistance to benznidazole,” Journal of Proteome Research, vol. 7, no. 6, pp. 2357–2367, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. J. A. Atwood, D. B. Weatherly, T. A. Minning et al., “Microbiology: the Trypanosoma cruzi proteome,” Science, vol. 309, no. 5733, pp. 473–476, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. P. L. Olliaro, P. J. Guerin, S. Gerstl, A. A. Haaskjold, J. A. Rottingen, and S. Sundar, “Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004,” Lancet Infectious Diseases, vol. 5, no. 12, pp. 763–774, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Blum, P. Desjeux, E. Schwartz, B. Beck, and C. Hatz, “Treatment of cutaneous leishmaniasis among travellers,” Journal of Antimicrobial Chemotherapy, vol. 53, no. 2, pp. 158–166, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Werbovetz, “Diamidines as antitrypanosomal, antileishmanial and antimalarial agents,” Current Opinion in Investigational Drugs, vol. 7, no. 2, pp. 147–157, 2006. View at Google Scholar · View at Scopus
  50. W. D. Wilson, F. A. Tanious, A. Mathis, D. Tevis, J. E. Hall, and D. W. Boykin, “Antiparasitic compounds that target DNA,” Biochimie, vol. 90, no. 7, pp. 999–1014, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. M. N. Soeiro, S. L. de Castro, E. M. de Souza, D. G. Batista, C. F. Silva, and D. W. Boykin, “Diamidine activity against trypanosomes: the state of the art,” Current Molecular Pharmacology, vol. 1, no. 2, pp. 151–161, 2008. View at Google Scholar · View at Scopus
  52. C. F. Silva, M. M. Batista, R. A. Mota et al., “Activity of “reversed” diamidines against Trypanosoma cruzi in vitro,” Biochemical Pharmacology, vol. 73, no. 12, pp. 1939–1946, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. C. F. Silva, M. B. Meuser, E. M. De Souza et al., “Cellular effects of reversed amidines on Trypanosoma cruzi,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 11, pp. 3803–3809, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. C. F. Da Silva, M. M. Batista, D. D. G. J. Batista et al., “In vitro and in vivo studies of the trypanocidal activity of a diarylthiophene diamidine against Trypanosoma cruzi,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 9, pp. 3307–3314, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. D. G. J. Batista, M. G. O. Pacheco, A. Kumar et al., “Biological, ultrastructural effect and subcellular localization of aromatic diamidines in Trypanosoma cruzi,” Parasitology, vol. 137, no. 2, pp. 251–259, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. E. M. De Souza, P. B. da Silva, A. S. Nefertiti et al., “Trypanocidal activity and selectivity in vitro of aromatic amidine compounds upon bloodstream and intracellular forms of Trypanosoma cruzi,” Experimental Parasitology, vol. 127, no. 2, pp. 429–435, 2011. View at Publisher · View at Google Scholar
  57. E. M. De Souza, A. Lansiaux, C. Bailly et al., “Phenyl substitution of furamidine markedly potentiates its anti-parasitic activity against Trypanosoma cruzi and Leishmania amazonensis,” Biochemical Pharmacology, vol. 68, no. 4, pp. 593–600, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. M. N. C. Soeiro, E. M. De Souza, C. E. Stephens, and D. W. Boykin, “Aromatic diamidines as antiparasitic agents,” Expert Opinion on Investigational Drugs, vol. 14, no. 8, pp. 957–972, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. E. M. de Souza, G. M. Oliveira, D. W. Boykin, A. Kumar, Q. Hu, and M. D. N. Soeiro, “Trypanocidal activity of the phenyl-substituted analogue of furamidine DB569 against Trypanosoma cruzi infection in vivo,” Journal of Antimicrobial Chemotherapy, vol. 58, no. 3, pp. 610–614, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. E. M. De Souza, G. M. Oliveira, and M. N. C. Soeiro, “Electrocardiographic findings in acutely and chronically Trypansoma cruzi-infected mice treated by a phenyl-substituted analogue of furamidine DB569,” Drug Targets Insights, vol. 2, no. 2, pp. 61–69, 2007. View at Google Scholar
  61. D. D. G. J. Batista, M. M. Batista, G. M. De Oliveira et al., “Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 7, pp. 2940–2952, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. N. S. Carter, B. J. Berger, and A. H. Fairlamb, “Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen- sensitive and -resistant Trypanosoma brucei brucei,” Journal of Biological Chemistry, vol. 270, no. 47, pp. 28153–28157, 1995. View at Publisher · View at Google Scholar · View at Scopus
  63. M. P. Barrett, R. J. S. Burchmore, A. Stich et al., “The trypanosomiases,” Lancet, vol. 362, no. 9394, pp. 1469–1480, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. P. G. Bray, M. P. Barrett, S. A. Ward, and H. P. De Koning, “Pentamidine uptake and resistance in pathogenic protozoa: past, present and future,” Trends in Parasitology, vol. 19, no. 5, pp. 232–239, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. A. M. Mathis, J. L. Holman, L. M. Sturk et al., “Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 6, pp. 2185–2191, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. A. M. Mathis, A. S. Bridges, M. A. Ismail et al., “Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 8, pp. 2801–2810, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Souto-Padron, N. L. Cunha e Silva, and W. de Souza, “Acetylated alpha-tubulin in Trypanosoma cruzi: immunocytochemical localization,” Memórias do Instituto Oswaldo Cruz, vol. 88, no. 4, pp. 517–528, 1993. View at Google Scholar · View at Scopus
  68. H. P. De Koning, “Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals,” Molecular Pharmacology, vol. 59, no. 3, pp. 586–592, 2001. View at Google Scholar · View at Scopus
  69. W. D. Wilson, B. Nguyen, F. A. Tanious et al., “Dications that target the DNA minor groove: compound design and preparation, DNA interactions, cellular distribution and biological activity,” Current Medicinal Chemistry and Anti-Cancer Agents, vol. 5, no. 4, pp. 389–408, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. G. Singh and C. S. Dey, “Induction of apoptosis-like cell death by pentamidine and doxorubicin through differential inhibition of topoisomerase II in arsenite-resistant Leishmania donovani,” Acta Tropica, vol. 103, no. 3, pp. 172–185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. A. C. Rosypal, J. E. Hall, S. Bakunova et al., “In vitro activity of dicationic compounds against a North American foxhound isolate of Leishmania infantum,” Veterinary Parasitology, vol. 145, no. 3-4, pp. 207–216, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. A. C. Rosypal, K. A. Werbovetz, M. Salem et al., “Inhibition by dications of in vitro growth of Leishmania major and Leishmania tropica: causative agents of old world cutaneous leishmaniasis,” Journal of Parasitology, vol. 94, no. 3, pp. 743–749, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. C. E. Stephens, R. Brun, M. M. Salem et al., “The activity of diguanidino and ‘reversed’ diamidino 2,5-diarylfurans versus Trypanosoma cruzi and Leishmania donovani,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 12, pp. 2065–2069, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. M. G. D. O. Pacheco, C. F. D. Silva, E. M. D. Souza et al., “Trypanosoma cruzi: activity of heterocyclic cationic molecules in vitro,” Experimental Parasitology, vol. 123, no. 1, pp. 73–80, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. A. Daliry, P. B. Da Silva, C. F. Da Silva et al., “In vitro analyses of the effect of aromatic diamidines upon Trypanosoma cruzi,” Journal of Antimicrobial Chemotherapy, vol. 64, no. 4, pp. 747–750, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Daliry, C. F. da Silva, P. B. da Silva, M. M. Batista, R. R. Tidwell, and M. N. C. Soeiro, “The biological in vitro effect and selectivity of aromatic dicationic compounds on Trypanosoma cruzi,” Memórias do Instituto Oswaldo Cruz, vol. 105, no. 3, pp. 239–245, 2010. View at Google Scholar · View at Scopus
  77. T. A. Shapiro and P. T. Englund, “The structure and replication of kinetoplast DNA,” Annual Review of Microbiology, vol. 49, pp. 117–143, 1995. View at Google Scholar · View at Scopus
  78. C. C. Dykstra, D. R. McClernon, L. P. Elwell, and R. R. Tidwell, “Selective inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells,” Antimicrobial Agents and Chemotherapy, vol. 38, no. 9, pp. 1890–1898, 1994. View at Google Scholar · View at Scopus
  79. A. Daliry, M. Munde, M. Q. Pires et al., “The trypanocidal activity of amidine compounds does not correlated with their binding affinity to parasite KDNA,” submitted to publication.
  80. M. Z. Wang, X. Zhu, A. Srivastava et al., “Novel arylimidamides for treatment of visceral leishmaniasis,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 6, pp. 2507–2516, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. E. Chiari, A. B. Oliveira, M. A. F. Prado, R. J. Alves, L. M. C. Galvão, and F. G. Araujo, “Potential use of WR6026 as prophylaxis against transfusion-transmitted American trypanosomiasis,” Antimicrobial Agents and Chemotherapy, vol. 40, supplement 3, pp. 613–615, 1996. View at Google Scholar · View at Scopus
  82. G. Powis, “Metabolism and reactions of quinoid anticancer agents,” Pharmacology and Therapeutics, vol. 35, no. 1-2, pp. 57–162, 1987. View at Google Scholar · View at Scopus
  83. P. J. O'Brien, “Molecular mechanisms of quinone cytotoxicity,” Chemico-Biological Interactions, vol. 80, no. 1, pp. 1–41, 1991. View at Publisher · View at Google Scholar · View at Scopus
  84. L. Costantino and D. Barlocco, “Privileged structures as leads in medicinal chemistry,” Current Medicinal Chemistry, vol. 13, no. 1, pp. 65–85, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. A. V. Pinto, R. F. S. Menna-Barreto, and S. L. De Castro, “Naphthoquinones isolated from Tabebuia: a review about the synthesis of heterocyclic derivatives, screeening against Trypanosoma cruzi and correlation structure-trypanocidal activity,” in Recent Progress in Medicinal Plants, J. N. Govil, Ed., vol. 16, pp. 112–127, Studium Press, Houston, Tex, USA, 2006. View at Google Scholar
  86. S. F. Villamil, A. O. M. Stoppani, and M. Dubin, “Redox cycling of β-lapachone and structural analogues in microsomal and cytosol liver preparations,” Methods in Enzymology, vol. 378, pp. 67–87, 2004. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Brunmark and E. Cadenas, “Redox and addition chemistry of quinoid compounds and its biological implications,” Free Radical Biology and Medicine, vol. 7, no. 4, pp. 435–477, 1989. View at Google Scholar · View at Scopus
  88. T. J. Monks, R. P. Hanzlik, G. M. Cohen, D. Ross, and D. G. Graham, “Quinone chemistry and toxicity,” Toxicology and Applied Pharmacology, vol. 112, no. 1, pp. 2–16, 1992. View at Publisher · View at Google Scholar · View at Scopus
  89. M. O. F. Goulart, P. Falkowski, T. Ossowski, and A. Liwo, “Electrochemical study of oxygen interaction with lapachol and its radical anions,” Bioelectrochemistry, vol. 59, no. 1-2, pp. 85–87, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. A. V. Pinto and S. L. De Castro, “The trypanocidal activity of naphthoquinones: a review,” Molecules, vol. 14, no. 11, pp. 4570–4590, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. T. J. Monks and D. C. Jones, “The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers,” Current Drug Metabolism, vol. 3, no. 4, pp. 425–438, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. R. Munday, B. L. Smith, and C. M. Munday, “Structure-activity relationships in the haemolytic activity and nephrotoxicity of derivatives of 1,2- and 1,4-naphthoquinone,” Journal of Applied Toxicology, vol. 27, no. 3, pp. 262–269, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. R. Munday, “Autoxidation of naphthohydroquinones: effects of pH, naphthoquinones and superoxide dismutase,” Free Radical Research, vol. 32, no. 3, pp. 245–253, 2000. View at Google Scholar · View at Scopus
  94. J. L. Bolton, M. A. Trush, T. M. Penning, G. Dryhurst, and T. J. Monks, “Role of quinones in toxicology,” Chemical Research in Toxicology, vol. 13, no. 3, pp. 135–160, 2000. View at Publisher · View at Google Scholar · View at Scopus
  95. B. Hazra, M. Das Sarma, and U. Sanyal, “Separation methods of quinonoid constituents of plants used in oriental traditional medicines,” Journal of Chromatography B, vol. 812, no. 1-2, pp. 259–275, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. S. L. Croft, J. Hogg, W. E. Gutteridge, A. T. Hudson, and A. W. Randall, “The activity of hydroxynaphthoquinones against Leishmania donovani,” Journal of Antimicrobial Chemotherapy, vol. 30, no. 6, pp. 827–832, 1992. View at Google Scholar · View at Scopus
  97. A. T. Hudson, “Atovaquone—a novel broad-spectrum anti-infective drug,” Parasitology Today, vol. 9, no. 2, pp. 66–68, 1993. View at Google Scholar · View at Scopus
  98. S. Sepúlveda-Boza and B. K. Cassels, “Plant metabolites active against Trypanosoma cruzi,” Planta Medica, vol. 62, no. 2, pp. 98–105, 1996. View at Publisher · View at Google Scholar · View at Scopus
  99. P. Arenas, “Medicine and magic among the Maka indians of the Paraguayan Chaco,” Journal of Ethnopharmacology, vol. 21, no. 3, pp. 279–295, 1987. View at Google Scholar · View at Scopus
  100. J. W. Bastien, “Pharmacopeia of Qollahuaya Andeans,” Journal of Ethnopharmacology, vol. 8, no. 1, pp. 97–111, 1983. View at Google Scholar · View at Scopus
  101. C. F. de Santana, O. de Lima, I. L. d' Albuquerque, A. L. Lacerda, and D. G. Martins, “Antitumoral and toxicological properties of extracts of bark and various wood components of Pau d'arco (Tabebuia avellanedae),” Revista do Instituto de Antibioticos, vol. 8, no. 1, pp. 89–94, 1968. View at Google Scholar · View at Scopus
  102. A. Boveris, R. Docampo, J. F. Turrens, and A. O. M. Stoppani, “Effect of β-lapachone on superoxide anion and hydrogen peroxide production in Trypanosoma cruzi,” Biochemical Journal, vol. 175, no. 2, pp. 431–439, 1978. View at Google Scholar · View at Scopus
  103. F. S. Cruz, R. Docampo, and W. De Souza, “Effect of β-lapachone on hydrogen peroxide production in Trypanosoma cruzi,” Acta Tropica, vol. 35, no. 1, pp. 35–40, 1978. View at Google Scholar · View at Scopus
  104. R. Docampo, F. S. Cruz, A. Boveris, R. P. Muniz, and D. M. Esquivel, “Lipid peroxidation and the generation of free radicals, superoxide anion and hydrogen peroxide in β-lapachone treated Trypanosoma cruzi epimastigotes,” Archives of Biochemistry and Biophysics, vol. 186, no. 2, pp. 292–297, 1978. View at Google Scholar
  105. S. G. Goijman and A. O. M. Stoppani, “Effects of β-lapachone, a peroxide-generating quinone, on macromolecule synthesis and degradation in Trypanosoma cruzi,” Archives of Biochemistry and Biophysics, vol. 240, no. 1, pp. 273–280, 1985. View at Google Scholar · View at Scopus
  106. M. P. Molina Portela, S. H. F. Fernandez Villamil, L. J. Perissinotti, and A. O. M. Stoppani, “Redox cycling of o-naphthoquinones in trypanosomatids. Superoxide and hydrogen peroxide production,” Biochemical Pharmacology, vol. 52, no. 12, pp. 1875–1882, 1996. View at Publisher · View at Google Scholar · View at Scopus
  107. A. O. M. Stoppani, “The chemotherapy of Chagas disease,” Medicina, vol. 59, supplement 2, pp. 147–165, 1999. View at Google Scholar · View at Scopus
  108. R. Docampo, J. N. Lopes, F. S. Cruz, and W. De Souza, “Trypanosoma cruzi: ultrastructural and metabolic alterations of epimastigotes by β lapachone,” Experimental Parasitology, vol. 42, no. 1, pp. 142–149, 1977. View at Google Scholar · View at Scopus
  109. J. N. Lopes, F. S. Cruz, R. Docampo et al., “In vitro and in vivo evaluation of the toxicity of 1,4-naphtoquinone and 1,2-naphthoquinone derivatives against Trypanosoma cruzi,” Annals of Tropical Medicine and Parasitology, vol. 72, no. 1, pp. 523–531, 1978. View at Google Scholar
  110. A. V. Pinto, M. C. F. R. Pinto, M. A. Aguiar, and R. S. Capella, “Transformações do lapachol em nafto-[1,2-b]-furanaquinonas naturais,” Anais da Academia Brasileira de Ciências, vol. 54, pp. 115–118, 1982. View at Google Scholar
  111. A. V. Pinto, V. F. Ferreira, M. C. F. R. Pinto, and L. U. Mayer, “Reaction of 2-amino-1,4-naphthoquinone derivatives with dimethyl acetylenedicarboxylate,” Synthetic Communications, vol. 15, no. 1, pp. 1181–1189, 1985. View at Google Scholar
  112. C. C. Lopes, R. S. C. Lopes, A. V. Pinto, and P. R. R. Costa, “Efficient synthesis of cytotoxic quinones: 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione,” Journal of Heterocyclic Chemistry, vol. 21, no. 2, pp. 621–622, 1984. View at Google Scholar · View at Scopus
  113. J. P. Chaves, M. C. F. R. Pinto, and A. V. Pinto, “Heterocyclics from quinones. I—reaction of lapachol with primary alkyl amines,” Journal of Brazilian Chemical Society, vol. 1, no. 3, pp. 21–27, 1990. View at Google Scholar
  114. S. L. de Castro, M. C. Pinto, and A. V. Pinto, “Screening of natural and synthetic drugs against Trypanosoma cruzi. 1. Establishing a structure/activity relationship,” Microbios, vol. 78, no. 315, pp. 83–90, 1994. View at Google Scholar · View at Scopus
  115. A. V. Pinto, C. N. Pinto, M. D. C. F. R. Pinto, R. S. Rita, C. A. C. Pezzella, and S. L. De Castro, “Trypanocidal activity of synthetic heterocyclic derivatives of active quinones from Tabebuia sp,” Arzneimittel-Forschung/Drug Research, vol. 47, no. 1, pp. 74–79, 1997. View at Google Scholar · View at Scopus
  116. C. N. Pinto, A. P. Dantas, K. C. G. De Moura et al., “Chemical reactivity studies with naphthoquinones from Tabebuia with anti-trypanosomal efficacy,” Arzneimittel-Forschung, vol. 50, no. 12, pp. 1120–1128, 2000. View at Google Scholar
  117. C. Neves-Pinto, V. R. S. Malta, M. D. C. F. R. Pinto, R. H. A. Santos, S. L. De Castro, and A. V. Pinto, “A trypanocidal phenazine derived from β-lapachone,” Journal of Medicinal Chemistry, vol. 45, no. 10, pp. 2112–2115, 2002. View at Publisher · View at Google Scholar · View at Scopus
  118. K. C. G. Moura, F. S. Emery, C. Neves-Pinto et al., “Synthesis and trypanocidal activity of naphthoquinones isolated from Tabebuia and heterocyclic derivatives: a review from an interdisciplinary study,” Journal of Brazilian Chemical Society, vol. 12, no. 3, pp. 325–338, 2001. View at Google Scholar
  119. K. C. G. De Moura, K. Salomão, R. F. S. Menna-Barreto et al., “Studies on the trypanocidal activity of semi-synthetic pyran[b-4,3] naphtho[1,2-d]imidazoles from β-lapachone,” European Journal of Medicinal Chemistry, vol. 39, no. 7, pp. 639–645, 2004. View at Publisher · View at Google Scholar · View at Scopus
  120. E. N. da Silva Jr., R. F. S. Menna-Barreto, M. D. C. F. R. Pinto et al., “Naphthoquinoidal [1,2,3]-triazole, a new structural moiety active against Trypanosoma cruzi,” European Journal of Medicinal Chemistry, vol. 43, no. 8, pp. 1774–1780, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. E. N. da Silva Jr., T. T. Guimarães, R. F. S. Menna-Barreto et al., “The evaluation of quinonoid compounds against Trypanosoma cruzi: synthesis of imidazolic anthraquinones, nor-β-lapachone derivatives and β-lapachone-based 1,2,3-triazoles,” Bioorganic and Medicinal Chemistry, vol. 18, no. 9, pp. 3224–3230, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. E. N. da Silva Jr., M. C.B.V. de Souza, M. C. Fernandes et al., “Synthesis and anti-Trypanosoma cruzi activity of derivatives from nor-lapachones and lapachones,” Bioorganic and Medicinal Chemistry, vol. 16, no. 9, pp. 5030–5038, 2008. View at Publisher · View at Google Scholar
  123. R. S. F. Silva, E. M. Costa, U. L. T. Trindade et al., “Synthesis ofnaphthofuranquinones with activity against Trypanosoma cruzi,” European Journal of Medicinal Chemistry, vol. 41, no. 4, pp. 526–530, 2006. View at Publisher · View at Google Scholar · View at Scopus
  124. R. F. S. Menna-Barreto, R. L. S. Gonçalves, M. Costa et al., “The activity against Trypanosoma cruzi of novel synthetic naphthoquinones is mediated by mitochondrial dysfunction and oxidative stress,” Free Radical Biology & Medicine, vol. 47, no. 5, pp. 644–653, 2009. View at Google Scholar
  125. R. F.S. Menna-Barreto, A. Henriques-Pons, A. V. Pinto, J. A. Morgado-Diaz, M. J. Soares, and S. L. De Castro, “Effect of a β-lapachone-derived naphthoimidazole on Trypanosoma cruzi: identification of target organelles,” Journal of Antimicrobial Chemotherapy, vol. 56, no. 6, pp. 1034–1041, 2005. View at Publisher · View at Google Scholar
  126. R. F. S. Menna-Barreto, J. R. Corrêa, A. V. Pinto, M. J. Soares, and S. L. De Castro, “Mitochondrial disruption and DNA fragmentation in Trypanosoma cruzi induced by naphthoimidazoles synthesized from β-lapachone,” Parasitology Research, vol. 101, no. 4, pp. 895–905, 2007. View at Publisher · View at Google Scholar · View at Scopus
  127. R. F. S. Menna-Barreto, J. R. Corrêa, C. M. Cascabulho et al., “Naphthoimidazoles promote different death phenotypes in Trypanosoma cruzi,” Parasitology, vol. 136, no. 5, pp. 499–510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  128. R. F. S. Menna-Barreto, K. Salomão, A. P. Dantas et al., “Different cell death pathways induced by drugs in Trypanosoma cruzi: an ultrastructural study,” Micron, vol. 40, no. 2, pp. 157–168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. F. Irigoín, L. Cibils, M. A. Comini, S. R. Wilkinson, L. Flohé, and R. Radi, “Insights into the redox biology of Trypanosoma cruzi: trypanothione metabolism and oxidant detoxification,” Free Radical Biology and Medicine, vol. 45, no. 6, pp. 733–742, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. R. F. S. Menna-Barreto, D. G. Beghini, A. T. S. Ferreira, A. V. Pinto, S. L. De Castro, and J. Perales, “A proteomic analysis of the mechanism of action of naphthoimidazoles in Trypanosoma cruzi epimastigotes in vitro,” Journal of Proteomics, vol. 73, no. 12, pp. 2306–2315, 2010. View at Publisher · View at Google Scholar
  131. J. H. Mckerrow, P. S. Doyle, J. C. Engel et al., “Two approaches to discovering and developing new drugs for Chagas disease,” Memórias do Instituto Oswaldo Cruz, vol. 104, no. 1, pp. 263–269, 2009. View at Google Scholar · View at Scopus
  132. Y. Ozaki, M. E. Guariento, and E. A. De Almeida, “Quality of life and depressive symptoms in Chagas disease patients,” Quality of Life Research, vol. 20, no. 1, pp. 133–138, 2011. View at Publisher · View at Google Scholar
  133. W. de Oliveira Jr., “All-around care for patients with Chagas disease: a challenge for the XXI century,” Memórias do Instituto Oswaldo Cruz, vol. 104, no. 1, pp. 181–186, 2009. View at Google Scholar · View at Scopus